Our highly trained physicians offer clinical trials for patients with cancer, HIV or immunodeficiency disorders. All trials take place at the NIH Clinical Center in Bethesda, MD, and through telehealth. Once you are enrolled in a clinical trial at the Clinical Center, medical care is free.
Center for Cancer Research
Creating the cancer medicines of tomorrow through bold biomedical research
Centrally supported by long-term funding and a culture of complete intellectual freedom, CCR scientists are able to pursue the most important and challenging problems in cancer research.
Our innovative training programs educate and mentor the next generation of researchers and physician-scientists, from summer students to faculty members. We can help you launch your career in basic, clinical, or translational research.
What can we help you find?
.@NCI_CCR_SB researchers led by Dr. Steven Rosenberg identified a genetic signature for elusive tumor-targeting T cells that helps locate these cells in tumors. This may speed up the process to make effective cancer #immunotherapies #Milestones2023 https://t.co/oljE6uCrWx https://t.co/eOH2j1mBgY
A multi-national consortium led by @NCIKenAldape conducted a detailed molecular analysis that revealed four distinct subtypes of #meningiomas, a common #braincancer. Read about this research and more in #Milestones2023! https://t.co/lSZiOQ5w72 https://t.co/p8Yw9qqsfs
This #Milestones2023 story is a “perfect example” of #precisiononcology. While most patients with #DLBCL didn’t benefit from a new combination treatment, a well-defined subset with one subtype did. Read more about the PHOENIX trial: https://t.co/lPO39ak8IY https://t.co/voCfYd1EHv
Join us on April 4&5 for the 4th NCI Symposium on Cancer Health Disparities! The event will highlight topics and ongoing research about systemic barriers and racism that lead to health disparities. Register by March 28 (in-person & virtual) #NCICHD23 https://t.co/qUELtNkIR3 https://t.co/Poax5BNfqC
CCR researchers led by @gulleyj1 and Dr. Mary Carrington found that cancer patients with the genetic marker HLA-A*03 may be less likely to respond to certain #immunotherapies. Read about this possible red flag for treatment in #Milestones2023 https://t.co/LEbu1ukEon https://t.co/1ev1ED0U0x
#HealthDisparities research led by Dr. Stefan Ambs and Dr. Allan Weissman has identified distinct molecular features in aggressive #prostatecancer and #breastcancer in African Americans. Read more in #Milestones2023 https://t.co/qUDjU7Eqa6 https://t.co/qvm9P94tRQ